587 results on '"de Ledinghen, V."'
Search Results
102. P0795 : Safety and efficacy of sofosbuvir-containing regimens in the French observational cohort ANRS CO22 HEPATHER
103. LO3 : Safety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients from the french observational cohort ANRS CO22 hepather*
104. G15 : The association of sofosbuvir and daclatasvir for treating severe recurrence of HCV infection after liver transplantation: Results from a large french prospective multicentric ANRS CO23 CUPILT cohort
105. P0468 : Negative impact of HBV/HCV coinfection on HBV or HCV monoinfection: Data from the French cohort – ANRS CO22 hepather
106. O109 : Treatment of severe HCV-recurrence after liver transplantation using sofosbuvir-based regimens: The ANRS CO23 CUPILT study
107. LP23 : Daclatasvir plus sofosbuvir with or without ribavirin in patients with HIV–HCV co-infection: interim analysis of a French multicenter compassionate use program
108. 2007 4 Week therapy with the non-nucleosidic polymerase inhibitor bi207127 in combination with peginterferon-alfa2a and ribavirin in treatment naive and treatment experienced chronic HCV GT1 patients
109. Prospective comparison of two algorithms combining non invasive tests for staging of liver fibrosis in chronic hepatitis C
110. P1062 3-YEAR TREATMENT WITH TENOFOVIR IN REAL-LIFE IS EFFECTIVE AND WELL TOLERATED IN CHB PATIENTS, INCLUDING THE ELDERLY AND PATIENTS WITH COMORBIDITIES
111. P835 LIVER STEATOSIS ASSESSMENT WITH CAP AT 3.5 MHz USING FIBROSCAN M AND XL PROBE
112. P1061 LONG-TERM TREATMENT WITH TENOFOVIR IN TREATMENT-NAIVE OR -EXPERIENCED CHB PATIENTS IS EFFECTIVE AND WELL TOLERATED IN REAL-LIFE PRACTICE: 3 YEARS RESULTS OF THE VIREAL STUDY
113. O83 NON-INVASIVE DIAGNOSIS OF LIVER FIBROSIS BY FIBROSCAN IN PATIENTS WITH ALCOHOLIC LIVER DISEASE: A META-ANALYSIS WITH INDIVIDUAL DATA
114. P1167 rs12979860 IL28B GENOTYPE IS ASSOCIATED WITH ADVANCED FIBROSIS IN HCV GENOTYPE 1-INFECTED EUROPEAN PATIENTS WITH CHRONIC HEPATITIS C: RESULTS FROM THE INTERNATIONAL GEN-C STUDY
115. O69 ALBUMIN INFUSION FOR BACTERIAL INFECTIONS OTHER THAN SPONTANEOUS BACTERIAL PERITONITIS IN CIRRHOTIC PATIENTS: A MULTICENTER RANDOMIZED CONTROLLED STUDY (ALB-CIRINF STUDY)
116. P203 Fibrose hépatique chez les patients diabétiques : rôles de la stéatose et de l’accumulation de produits de glycation avancée
117. Daclatasvir combined with peginterferon alfa-2a and ribavirin for 12 or 16 weeks in patients with hepatitis C virus genotype 2 or 3 infection: COMMAND GT2/3 study
118. DACLATASVIR COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN FOR 12 OR 16 WEEKS IN PATIENTS WITH HCV GENOTYPE 2 OR 3 INFECTION: COMMAND GT2/3 STUDY
119. Twelve- or 16-Week Treatment With Daclatasvir Combined With Peginterferon Alfa and Ribavirin for Hepatitis C Virus Genotype 2 or 3 Infection: Command GT2/3 Study
120. SAT-477 - Liver Fibrosis Diagnosis by Blood Test and Elastography: Agreement or Combination?
121. SAT-007 - The Benefits of Virosuppression on Progression of Portal Hypertension in Patients with Compensated Viral Cirrhosis (ANRS CO12 CirVir Cohort)
122. FRI-481 - Renal Dysfunction in Liver Transplant Patients Treated with Sofosbuvir Based-Regimen for HCV Recurrence: Results from a Large French Prospective Multicentric ANRS CO23 Cupilt
123. FRI-483 - Sofosbuvir-Based-Regimen for HCV Recurrence after Combined Liver-Kidney Transplantation : Results from the ANRS CO23 Cupilt Study
124. THU-352 - Extrahepatic Cancer is the Second Cause of Non Liver-Related Death in Patients with Compensated Viral Cirrhosis and is Associated with Viral Replication (ANRS CO12 CirVir Prospective Cohort)
125. PS116 - Prospective Evidence That Hepatocellular Carcinoma Surveillance in Patients with Compensated Viral Cirrhosis Increases the Probability of Curative Treatment and Survival Taking into Account Lead-Time Bias (Anrs Co12 Cirvir Cohort)
126. PS088 - New Recommendations of Baveno Vi Conference for the Screening of Portal Hypertension: An Independent Sequential Validation in Patients with Compensated Viral Cirrhosis Taking into Account Virological Status (Anrs Co12 Cirvir Cohort)
127. Hepatitis E virus infection as a new probable cause ofde novomembranous nephropathy after kidney transplantation
128. 765 TWELVE-MONTHS ENTECAVIR LONGITUDINAL CHANGES IN LIVER FIBROSIS, ACTIVITY AS PER FibroTest-FibroMax AND LIVER STIFFNESS MEASUREMENTS IN CHRONIC HEPATITIS B. STEATOSIS IMPACT ON FIBROSIS REGRESSION
129. 60 SVR12 RATES AND SAFETY OF TRIPLE THERAPY INCLUDING TELAPREVIR OR BOCEPREVIR IN 221 CIRRHOTIC NON RESPONDERS TREATED IN THE FRENCH EARLY ACCESS PROGRAM (ANRS CO20-CUPIC)
130. 112 INCIDENCE AND PREDICTIVE FACTORS OF HEPATOCELLULAR CARCINOMA AND COMPLICATIONS IN HBV- OR HCV-RELATED COMPENSATED CIRRHOSIS. A MULTICENTER PROSPECTIVE COHORT IN 1653 PATIENTS (ANRS CO12 CirVir)
131. 1422 END OF TREATMENT RESPONSE AFTER PROTEASE INHIBITOR (PI)- BASED THERAPY FOR HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION: A MULTICENTRIC EUROPEAN EXPERIENCE
132. 719 COMPARISON OF THE NAFLD FIBROSIS SCORE VERSUS 7 OTHER BLOOD TESTS FOR LIVER FIBROSIS IN NAFLD
133. 983 CHRONIC HEPATITIS B SCREENING IN FRANCE: IMPROVEMENT IS STILL NEEDED
134. 1094 100% SVR IN IL28B CC PATIENTS TREATED WITH 12 WEEKS OF TELAPREVIR, PEGINTERFERON AND RIBAVIRIN IN THE PROVE2 TRIAL
135. PERFORMANCES OF ELASTO-FIBROTEST®, A COMBINATION BETWEEN FIBROTEST AND LIVER STIFFNESS MEASUREMENTS FOR ASSESSING THE STAGE OF LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C
136. 1045 SEVERAL PATHOLOGICAL LESIONS INFLUENCE NON-INVASIVE TESTS OF LIVER FIBROSIS
137. 8 SAFETY OF TELAPREVIR OR BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA/RIBAVIRIN, IN CIRRHOTIC NON RESPONDERS. FIRST RESULTS OF THE FRENCH EARLY ACCESS PROGRAM (ANRS CO20-CUPIC)
138. 1043 NON-INVASIVE DIAGNOSIS OF FIBROSIS IN NAFLD: COMBINATION OF FIBROSCAN WITH BLOOD MARKERS IS MORE ACCURATE THAN SINGLE FIBROSIS TESTS
139. P261 Infliximab trough levels in patients' developping cutaneous and rheumatologic paradoxical manifestations: A case control study
140. P070 La stéatose hépatique des patients biopsiés pour NASH est associée à leurs apports alimentaires glucidiques
141. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan®: validation in chronic hepatitis C
142. P14 - Les conseils diététiques ont davantage d’effets chez les femmes atteintes de NASH (Non Alcoholic Steato Hepatitis)
143. 21 NON INVASIVE DIAGNOSIS OF STEATOSIS USING CAP BY FIBROSCAN®. A PROSPECTIVE STUDY
144. 324 COMPARISON OF DIAGNOSTIC ALGORITHMS FOR LIVER FIBROSIS IN HEPATITIS C. NEW ALGORITHMS ARE AS EFFECTIVE WHILE MORE PRECISE AND TOTALLY NON-INVASIVE
145. 325 NON-INVASIVE DIAGNOSIS OF CIRRHOSIS IN CLINICAL PRACTICE IN HEPATITIS C
146. 327 XL PROBE OF FIBROSCAN® IN PATIENTS WITH CHRONIC LIVER DISEASE. A PROSPECTIVE EVALUATION IN COMPARISON WITH LIVER BIOPSY, M PROBE, FIBROTEST AND APRI
147. 323 DETERMINATION OF RELIABILITY CRITERIA FOR LIVER STIFFNESS EVALUATION IN A COHORT OF 1165 PATIENTS
148. 365 INACTIVE HBV CARRIERS: IS LIVER STIFFNESS MEASUREMENT USEFUL? A MULTICENTRE PROSPECTIVE STUDY
149. P1262 : An accurate score for the prediction of sustained viral response under protease inhibitor-based triple therapy in cirrhotic patients: The cupic algorithm – the ANRS CO20 CUPIC study
150. P1266 : Human albumin use in cirrhotic patients in France: Results of the national “Albu-live” survey
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.